Je Il Pharmaceutical Co., Ltd.

Wellmarker Bio Co., Ltd.

Yuyu Pharma, Inc.

Chun-Ho Park

Hyunho Lee

Jong-Hee Choi

In-Hae Ye

Joseph Kim

HyoJin Kim

Hyojin Kim

Seung-Hyun Kim

Myung-Hwa Kim

Jai-Hee Moon

Hyebin Park

Kwang-Woo Chun

Seung-Woo Hong

Taegon Baik

Yoon-Sun Park

Sae-Kwang Ku

Bo-Young Joe

Jeongmin Kim

Kwangwoo Chun

Eunsung Jang

Yoonsun Park

Dong-Kyu Ryu

Ji-Seon Park

Han-Chang Lee

Ji-So Choi

Young-Chul Kim

Sun Chul Hur

Jae-Sik Shin

Sohee Lee

Gyoung-Wook Min

Dong-il Kang

Jong-Yun Choi

The present invention relates to novel peptides and a pharmaceutical compositions comprising the same. The peptide compounds and compositions disclosed herein are useful as therapeutic agents for treating eye diseases. When administered to the eyes, the peptide compounds and compositions disclosed herein increase the amount of tear secretion and promotes recovery of a damaged cornea.

Peptides and pharmaceutical compositions for treating eye diseases

A thienopyridine derivative compound represented by Formula 1 or pharmaceutically acceptable salts thereof have an excellent inhibitory effect on protein kinase activity, and accordingly, pharmaceutical compositions containing the thienopyridine compound can be usefully used for the prevention or treatment of a disease associated with the activity of a protein kinase.

Thienopyridine derivatives and pharmaceutical composition comprising same

The present disclosure relates to novel imidazo[1,2-a]pyridine derivatives, and more particularly to imidazo[1,2-a]pyridine derivatives of Formula 1 

Imidazo[1,2-A]pyridine derivatives, methods for preparing the same and use thereof

The present invention relates to a novel crystalline acid salt of a tricyclic derivative or a hydrate thereof and a production method thereof. The crystalline acid salt or the hydrate thereof according to the present invention is stable with respect to humidity and stable with respect to hygroscopicity, and the quality control during manufacturing drugs is favorable. In addition, the crystalline acid salt or the hydrate thereof may be used in a pharmaceutical composition for preventing or treating neuropathic pain, epilepsy, stroke, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, schizophrenia, chronic and acute pain, ischemic brain injury, neuronal loss after hypoxia, trauma and nerve damage, which are medical conditions induced by PARP overactivity.

Crystalline forms of tricyclic compound acid salt or hydrate thereof, and method for making thereof

The present invention relates to a novel tricyclic derivative with efficient inhibitory activity against poly(ADP-ribose)polymerases (PARP) or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition containing the same. The tricyclic derivative of the invention is useful for the prevention or treatment of diseases caused by excess PARP activity, especially neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic nephropathy, inflammatory diseases, osteoporosis, and cancer, by inhibiting the activity of poly(ADP-ribose)polymerases.

Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same

Growing community of inventors

Yongin-si, South Korea

Chun-Ho Park